BusinessVaccinex, Inc. to Host Key Opinion Leader Luncheon on Huntington’s DiseaseBy Nasdaq OMXJan 30, 2018, 4:14 PM UTC
BusinessVaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease)By Nasdaq OMXApr 24, 2017, 2:28 PM UTC
BusinessVaccinex, Inc. Announces Continuation of the SIGNAL Clinical TrialBy Nasdaq OMXSep 9, 2016, 1:45 PM UTC
